Neu­ro­crine ax­es Parkin­son's col­lab with Voy­ager af­ter safe­ty is­sues, jeop­ar­diz­ing biotech's long-run­ning cen­ter­piece

Six years ago, Third Rock Ven­tures launched Voy­ager Ther­a­peu­tics with $45 mil­lion and a goal of bring­ing gene ther­a­py in­to some of the most no­to­ri­ous neu­ro­log­i­cal dis­eases, most no­tably Parkin­son’s. Now that pro­gram, long their lead and on­ly clin­i­cal as­set, is in jeop­ardy.

Voy­ager an­nounced Tues­day af­ter­noon that Neu­ro­crine Bio­sciences has ter­mi­nat­ed their agree­ment to co-de­vel­op the Parkin­son’s gene ther­a­py af­ter safe­ty is­sues put the pro­gram on hold last year. Voy­ager said they are still eval­u­at­ing whether or not to con­tin­ue de­vel­op­ing the gene ther­a­py in­ter­nal­ly. They pinned Neu­ro­crine’s de­ci­sion on a “port­fo­lio re­view and pri­or­i­ti­za­tion of its cur­rent pipeline as­sets.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER